7 / 14
Page 29
Volume 3
Microbiology 2019 & Fungal infections 2019
October 07-08, 2019
Journal of Clinical Microbiology and Infectious diseases
October 07-08, 2019 | Madrid, Spain
MICROBIOLOGY AND MICROBIOLOGISTS
MYCOLOGY AND FUNGAL INFECTIONS
2
nd
Annual Congress on
6
th
International Conference on
&
J Clin Microbiol Infect Dis, Volume 3
Novel treatment of disseminated Coccidioidomycosis in a dog with voriconazole
Chantel Raghu, Care Center, USA
Chris Reagh, Oxford Veterinary Hospital, USA
C
occidioides
is endemic in some areas of the southwestern United States, Mexico, and SouthAmerica, and it was most recently
found in south central Washington. The treatment of choice for
Coccidioides
in humans depends on severity, chronicity, and
anatomic involvement. In humans, fluconazole is the agent of choice and amphotericin B is often used for rapidly progressive
coccidiodal infections. Newly available antifungal drugs that may be beneficial in refractory cases include voriconazole,
caspofungin, and posaconazole. There have been a few case reports and one case study documenting successful treatment of
disseminated Coccidioidomycosis in human patients using voriconazole. In dogs, management of Coccidioidomycosis involves
long-term antifungal drug treatment, typically with azoles such as ketoconazole, itraconazole, or fluconazole. Amphotericin B is
recommended in cases of severe, diffuse pulmonary infections to achieve a faster onset of action when compared to azoles. Dogs
with disseminated Coccidioidomycosis carry a grave prognosis despite standard treatment with fluconazole. This case report
describes the successful management of a dog with disseminated Coccidioidomycosis involving the skeletal, cutaneous, and
pulmonary systems with voriconazole after failing traditional therapy with fluconazole and terbinafine. This report is the first to
describe the successful management of refractory Coccidiodomycosis with voriconazole in a dog.
chantelraghu@carecentervets.com